Invention Grant
US08168663B2 Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
有权
6-羧基-2-（3,5-二氯苯基） - 苯并恶唑的药学上可接受的盐，以及包含其盐的药物组合物
- Patent Title: Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
- Patent Title (中): 6-羧基-2-（3,5-二氯苯基） - 苯并恶唑的药学上可接受的盐，以及包含其盐的药物组合物
-
Application No.: US12481527Application Date: 2009-06-09
-
Publication No.: US08168663B2Publication Date: 2012-05-01
- Inventor: Jeffery W. Kelly , Evan T. Powers , Hossein Razavi
- Applicant: Jeffery W. Kelly , Evan T. Powers , Hossein Razavi
- Applicant Address: US CA La Jolla
- Assignee: The Scripps Research Institute
- Current Assignee: The Scripps Research Institute
- Current Assignee Address: US CA La Jolla
- Agency: Jones Day
- Main IPC: A61K31/423
- IPC: A61K31/423
Abstract:
Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.
Public/Granted literature
- US20100120919A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES Public/Granted day:2010-05-13
Information query
IPC分类:
